COMPANY PROFILE

Eikonizo Therapeutics

Explore full profile

Developing therapies to improve the treatment of human disease, specifically neurodegenerative diseases

Cambridge, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2023

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Eikonizo Therapeutics

Eikonizo Therapeutics is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. The company specializes in creating brain-penetrant small molecules that inhibit HDAC6, an enzyme implicated in conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD). By targeting HDAC6, Eikonizo aims to preserve axonal transport and reduce protein aggregates, thereby slowing or halting disease progression. Eikonizo operates in the biopharmaceutical market, serving patients suffering from neurodegenerative disorders. The company's business model revolves around research and development (R&D) of novel therapeutics, which are then brought to market through clinical trials and regulatory approval processes. Revenue is generated through partnerships, licensing agreements, and eventual sales of approved therapies. Keywords: neurodegenerative, HDAC6 inhibitor, brain-penetrant, ALS, Alzheimer's, axonal transport, protein aggregates, biopharmaceutical, R&D, therapeutic development.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Cambridge, United States
Employees: 13
Open positions: None listed
Dealroom signal: 71.3/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Neurology, Alzheimers Disease, Degenerative Diseases, Chronic Disease, Spinout, Sustainable Development Goals, Biotech and Pharma
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Dec 2024	$0	—	Novo Nordisk	↗
SERIES A✓Equity / VC	Dec 2023	$40M	$160M	Undisclosed	↗

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Eikonizo Therapeutics website traffic

Latest recorded traffic for Eikonizo Therapeutics is 30 monthly website visits, down 76.9% over the last three months. Eikonizo Therapeutics's team declined 7.1% over the past year.

Latest monthly visits30 3-month web change-76.9% 1-year team growth-7.1%

Monthly website visitsNov 2022–May 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SESea4UsSea4Us is a biopharmaceutical startup specializing in discovering and developing new drugs, leveraging expertise in ion channels and marine biology	Vila do Bispo, Portugal	Operational	26	$6.2M	$23M
ANAspen NeuroscienceBiotechnology company that uses innovative genomic approaches combined with stem cell biology	San Diego, United States	Operational
PDPre DiagnosticsAn innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases	Oslo, Norway	Operational
NANatInLabDeveloping AI‑driven protease inhibitor drugs targeting neurodegenerative diseases	Amsterdam, Netherlands	Operational
STScripta TherapeuticsAI-driven drug discovery modulating transcription factor activity	Oxford, United Kingdom	Operational
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational
VTVima TherapeuticsOral treatments for dystonia, enhancing mobility and quality of life for over 1 million affected individuals in the US	Cambridge, United States	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational